Skip to main content
. 2018 Aug 10;9(62):32054–32062. doi: 10.18632/oncotarget.25889

Figure 1. Clinical features during OBV/PTV/r treatment.

Figure 1

(A) Changes in the amount of HCV-RNA during OBV/PTV/r treatment. (B) Changes in the level of ALT during OBV/PTV/r treatment. One patient experienced a grade 4 side effect at week 8 and failed to complete the OBV/PTV/r treatment.